Learning Hub Central
Immunotherapy
-1759606534764.webp&w=3840&q=75)
2025 SPS Seattle | A Review of Expanding PD-1 / PD-L1 Therapies
Immunotherapy
Non-CME Credit Course
-1759606327403.webp&w=3840&q=75)
2025 SPS Seattle | Site-of-Care Practical and Economic Considerations for CAR-T Therapy
Immunotherapy
Non-CME Credit Course
-1755988066641.webp&w=3840&q=75)
2025 CCC | Immune Related Adverse Events
Immunotherapy
Non-CME Credit Course
-1755987918967.webp&w=3840&q=75)
2025 CCC | Immunotherapy Biomarkers: What’s Next
Immunotherapy
Non-CME Credit Course
-1753360571959.webp&w=3840&q=75)
2025 NOSCM | Immunotherapy in First Line Metastatic Setting
Immunotherapy
Non-CME Credit Course
-1752957139171.webp&w=3840&q=75)
2025 NOSCM | Melanoma: Novel Advances in Immunotherapy
Immunotherapy
Non-CME Credit Course
-1752957036180.webp&w=3840&q=75)
2025 NOSCM | Innovations in Thoracic Oncology in 20 Years
Immunotherapy
Non-CME Credit Course
-1752954591090.webp&w=3840&q=75)
2025 NOSCM | Immunotherapy in Head and Neck Cancers
Immunotherapy
Non-CME Credit Course
Immunotherapy for Breast Cancer: When to Use and Future Directions
Immunotherapy
Non-CME Credit Course
2024 NOSCM | Cervical and Uterine Cancer: Novel Advances in Personalized Medicine in 2024
Immunotherapy
Non-CME Credit Course
2024 NOSCM | Squamous Cell Carcinoma of Head and Neck: Where Are We in 2024?
Immunotherapy
Non-CME Credit Course
2024 MCM | New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?
Immunotherapy
Non-CME Credit Course
2024 MCM | What To Do When Patients Getting Immunotherapy Do Not Respond to Steroids (Hepatitis, Colitis, Pneumonitis, and Others)
Immunotherapy
Non-CME Credit Course
2024 MLS Cleveland | Immunotherapy Updates in Melanoma
Immunotherapy
Non-CME Credit Course
2024 MLS Cleveland | Immunotherapy Updates in Breast Cancer
Immunotherapy
Non-CME Credit Course
2024 MLS Cleveland | Immunotherapy and HER2 Targeted Updates in Esophageal Cancer
Immunotherapy
Non-CME Credit Course
2024 MLS Cleveland | Immunotherapy and BiTe Treatment Updates in Prostate Cancer
Immunotherapy
Non-CME Credit Course
2024 MLS Cleveland | Immunotherapy and ADC Updates in Urothelial Cancers
Immunotherapy
Non-CME Credit Course
2024 MLS Cleveland | Immunotherapy Updates in Head and Neck Cancer
Immunotherapy
Non-CME Credit Course
Establishing Immunotherapy Management in Gastrointestinal Cancers
Immunotherapy
Non-CME Credit Course
Immunotherapy and Targeted Agents in Head/Neck Cancer
Immunotherapy
Non-CME Credit Course
Novel Immunotherapy Approach and Targeted Therapy in Melanoma
Immunotherapy
Non-CME Credit Course
Perioperative Immunotherapy in Non-Small Cell Lung Cancer
Immunotherapy
Non-CME Credit Course
Current and Future Directions of Immunotherapy for Breast Cancer
Immunotherapy
Non-CME Credit Course
Immunotherapy For Triple Negative Breast Cancer Optimal Chemotherapy Partners, New Directors, And Managing Toxicity
Immunotherapy
Non-CME Credit Course
2022 AIO | Updates in CAR T Therapies
Immunotherapy
Non-CME Credit Course
Role of Interleukins in TIME to Improve Immunotherapy Efficacy
Immunotherapy
Non-CME Credit Course
What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?
Immunotherapy
Non-CME Credit Course
The Role of Co-Mutations with Immunotherapy Response in NSCLC
Immunotherapy
Non-CME Credit Course
The New Role of Microbiome in Lung Cancer Immunotherapy
Immunotherapy
Non-CME Credit Course
The Importance of TIME in Cancer Fight: How to Target It?
Immunotherapy
Non-CME Credit Course
Neoadjuvant Immunotherapy Position
Immunotherapy
Non-CME Credit Course
Future Challenges for Immunotherapy in the Fight Against NSCLC
Immunotherapy
Non-CME Credit Course
Adjuvant Immunotherapy Position
Immunotherapy
Non-CME Credit Course
2024 SPECTRUM | Combined Angio-CT system – Precision therapy in IO
Immunotherapy
Non-CME Credit Course
2024 SPECTRUM | Precision Imaging in IO
Immunotherapy
Non-CME Credit Course
Metastatic NSCLC Immunotherapy Updates
Immunotherapy
Non-CME Credit Course
2021 CCC | Management of Immune Related Adverse Events
Immunotherapy
Non-CME Credit Course
2023 CCC | Advances in Car-T Cells Development for Cancer Therapy
Immunotherapy
Non-CME Credit Course
2023 CCC | Advances in Non-PD(L)1 Immunotherapies
Immunotherapy
Non-CME Credit Course
Management of Neurological Toxicities from Immunotherapy: Diagnosis, Assessement and Therapy
Immunotherapy
Non-CME Credit Course
2021 NOSCM | Toxicities in Immunotherapy
Immunotherapy
Non-CME Credit Course
Immunotherapy in Kidney & Bladder Cancer
Immunotherapy
Non-CME Credit Course
Immunotherapy for Breast Cancer: Current and Future Directions
Immunotherapy
Non-CME Credit Course
How to Combine RT and Immunotherapy Without Compromising Anti-tumor Effect?
Immunotherapy
Non-CME Credit Course
Metastatic Lung Immunotherapy Updates
Immunotherapy
Non-CME Credit Course
What After Immunotherapy Failure in First Line: Is There Hope?
Immunotherapy
Non-CME Credit Course
Favoring The Neoadjuvant Concept
Immunotherapy
Non-CME Credit Course
Immunotherapy in Advanced NSCLC: Initial Therapy and How to Overcome Resistance
Immunotherapy
Non-CME Credit Course
Immunotherapy for GU Malignancies and Exciting Developments
Immunotherapy
Non-CME Credit Course
Most Common Adverse Events of Checkpoint Inhibitors | Current Recommendations and Management
Immunotherapy
Non-CME Credit Course
Immunotherapy for Early-Stage Lung Cancer: Adjuvant and Neoadjuvant Approaches
Immunotherapy
Non-CME Credit Course
TNBC and Immunotherapy Developments in Breast Cancer
Immunotherapy
Non-CME Credit Course
Immunotherapy
Immunotherapy
Non-CME Credit Course
2022 CCC | Advances in Car-T Cells and Other Cellular Based Therapies
Immunotherapy
Non-CME Credit Course
2022 CCC | The Future of Biomarkers of Immunotherapy in Cancer
Immunotherapy
Non-CME Credit Course
2022 NOSCM | Immunotherapy in Non-Melanoma Skin Cancers (BCC, Squamous & Merkel) and What After IO Failure?
Immunotherapy
Non-CME Credit Course
2022 NOSCM | Immunotherapy, Targeted Therapy & And What After in Melanoma?
Immunotherapy
Non-CME Credit Course
2022 NOSCM | Immunotherapy in Head & Neck Cancer and What After IO Failure?
Immunotherapy
Non-CME Credit Course
2022 MLS Nashville | Keynote Lecture: CAR-T Cell and Cellular Therapy Update
Immunotherapy
Non-CME Credit Course
The Rule of Immunotherapy in the Treatment of Relapse Hodgkin Lymphoma
Immunotherapy
Non-CME Credit Course
Immunotherapy in Gynecologic Malignancies
Immunotherapy
Non-CME Credit Course
2022 MCM | Immunotherapy for Melanoma
Immunotherapy
Non-CME Credit Course
Immunotherapy in Kidney & Bladder Tumors
Immunotherapy
Non-CME Credit Course
Immunotherapy for Breast Cancer: Updates and New Directions
Immunotherapy
Non-CME Credit Course
Role of Immunotherapy in HNC
Immunotherapy
Non-CME Credit Course
2021 NOSCM | Chimeric Antigen Receptor T-Cell Therapy: Indications and Remaining Challenges
Immunotherapy
Non-CME Credit Course
2021 MCM | Immunotherapy Session
Immunotherapy
Non-CME Credit Course
Progress in CAR-T Cell Therapies
Immunotherapy
Non-CME Credit Course
Immunotherapy in Oncology Session II
Immunotherapy
Non-CME Credit Course
Immunotherapy in Oncology Session I
Immunotherapy
Non-CME Credit Course
Immunotherapy in Breast Cancer: Recent Updates
Immunotherapy
Non-CME Credit Course
Immunotherapy in Metastatic NSCLC: Frontline and What’s After Immunotherapy Failure
Immunotherapy
Non-CME Credit Course
Cancer Immunotherapy
Immunotherapy
Non-CME Credit Course
Case Presentation - Lung - Immunotherapy Toxicity Case, How to Manage and Whether to Permanently Stop or Not
Immunotherapy
Non-CME Credit Course
Updates in Immunotherapy & Targeted Therapy in Gastrointestinal Cancers
Immunotherapy
Non-CME Credit Course
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from February 2020
Immunotherapy
Non-CME Credit Course
Immunotherapy selection in mRCC
Immunotherapy
Non-CME Credit Course
Lung Cancer Immunotheraphy Case Presentation
Immunotherapy
Non-CME Credit Course
Promising Immunotherapy for Melanoma
Immunotherapy
Non-CME Credit Course
Advances in Immunotherapy
Immunotherapy
Non-CME Credit Course
Immunotherapy for Advanced Non-Small Cell Lung Cancer
Immunotherapy
Non-CME Credit Course
New Immunotherapeutic Strategies Checkpoint Inhibitors and Beyond
Immunotherapy
Non-CME Credit Course
Combination Radiation and Immunotherapy
Immunotherapy
Non-CME Credit Course
Handling Common Toxicities of Immune Checkpoint Inhibitors
Immunotherapy
Non-CME Credit Course
Challenges in Immunotherapy in NSCLC
Immunotherapy
Non-CME Credit Course
Immunotherapy and Side Effect Management: Challenging Cases
Immunotherapy
Non-CME Credit Course
Optimizing Immunotherapy with Radiation
Immunotherapy
Non-CME Credit Course
Immunotherapy for Advanced NSCLC
Immunotherapy
Non-CME Credit Course
Systemic Immunotherapy Combinations
Immunotherapy
Non-CME Credit Course
Challenges in Breast Cancer Immunotherapy
Immunotherapy
Non-CME Credit Course
Immunotherapy for Kidney and Bladder Malignancies
Immunotherapy
Non-CME Credit Course
Emerging Biomarkers for Immunotherapy in NSCLC
Immunotherapy
Non-CME Credit Course
Common Misunderstandings in IO
Immunotherapy
Non-CME Credit Course
Radiotherapy & Immunotherapy Applications in Oncology
Immunotherapy
Non-CME Credit Course
Immunotherapy in Cancer: A Primer on Biomarkers and Mechanism of Action
Immunotherapy
Non-CME Credit Course
Case Presentation - Lung - Immunotherapy Toxicity Case, How to Manage and Whether toPermanently Stop or Not
Immunotherapy
Non-CME Credit Course
Handling the Most Common Toxicities fromIO - Endocrinopathies, Pneumonitis, SkinRash-Pruritus, and Adrenal Insufficiency
Immunotherapy
Non-CME Credit Course
Management of Immune Related Adverse Events “the guard dog that attacks the owner”
Immunotherapy
Non-CME Credit Course
Immunotherapy for Breast
Immunotherapy
Non-CME Credit Course
Combination Immunotherapy for Lung Cancer
Immunotherapy
Non-CME Credit Course
Immunotherapy in Colorectal Cancer
Immunotherapy
Non-CME Credit Course
Case Study Immunotherapy
Immunotherapy
Non-CME Credit Course
Case Study on Immunotherapy Reaction
Immunotherapy
Non-CME Credit Course
Immunotherapy Related Adverse Reactions
Immunotherapy
Non-CME Credit Course
Immunotherapy in NSCLC: Advanced Disease and Resistance
Immunotherapy
Non-CME Credit Course
Immunotherapy for Upper GI Cancers
Immunotherapy
Non-CME Credit Course
Management of Most Common Toxicities Seen with Checkpoint Inhibitors
Immunotherapy
Non-CME Credit Course
Frontline: What are We Adding to Checkpoint Inhibitors and Chemotherapy?
Immunotherapy
Non-CME Credit Course
ROS-1 & B-Raf Inhibitors: New Developments
Immunotherapy
Non-CME Credit Course
KRAS: Deciphering the Mechanism of Resistance To First Generation KRAS Inhibitors
Immunotherapy
Non-CME Credit Course
Immune-Related Adverse Events (irAE) Checkpoint Inhibitors
Immunotherapy
Non-CME Credit Course
Overcoming T-Cell Exhaustion
Immunotherapy
Non-CME Credit Course
Incorporating Immunotherapy and Novel Biological Agents in Breast Cancer
Immunotherapy
Non-CME Credit Course
Targeting the Microbiome and Optimizing Immunotherapy in Cancer
Immunotherapy
Non-CME Credit Course
Combining Immunotherapy with Radiation for LA-NSCLC
Immunotherapy
Non-CME Credit Course
Debate- Is Perioperative Immunotherapy the New Standard of Care? No.
Immunotherapy
Non-CME Credit Course
Debate- Is Perioperative Immunotherapy the New Standard of Care? Yes.
Immunotherapy
Non-CME Credit Course
Perioperative Chemo/Immunotherapy and Surgical Outcomes
Immunotherapy
Non-CME Credit Course
2024 NOSCM | Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies-- Focus on PARPi and Other Targeted Therapies
Immunotherapy
Non-CME Credit Course
2024 NOSCM | Melanoma: Novel Advances in Immunotherapy
Immunotherapy
Non-CME Credit Course
Contact Us
